Loading...
01/10 22:45
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Recursion's earnings call presented a mixed but generally positive outlook. The company showcased strong financial health, with significant cash reserves and reduced cash burn projections. Strategic partnerships with major players like Sanofi and Roche are advancing, and the company is leveraging AI for drug development. Despite some uncertainties in clinical trials and platform integration, the optimistic guidance and potential milestone achievements suggest a positive sentiment. The market cap suggests moderate volatility, supporting a positive stock price movement prediction in the 2% to 8% range.
Cash Balance $533 million at the end of the quarter, with a commitment to manage expenses efficiently. This represents a 35% reduction in expected cash burn by 2026 compared to 2024 levels. Reasons for change include efficient expense management and inflows such as a $29 million R&D tax credit and milestone payments from partnerships.
Cash Burn Expected to be below $390 million in 2026, a 35% reduction from 2024 levels. This reduction is attributed to efficient expense management and strategic financial planning.
R&D Tax Credit $29 million received as a U.K. tax credit during the quarter. Future credits will be smaller due to legislative changes.
Partnership Inflows Projected to exceed $100 million by the end of 2026. This includes milestone payments from partnerships such as Sanofi.
Recursion OS 2.0: Integration of components from Exscientia and Recursion to create an end-to-end capability from target discovery to clinical trial simulation. Incorporation of Boltz-2 technology for protein folding and ligand binding predictions, achieving 1,000-fold less compute requirements.
ClinTech platform: Deployed across all programs, enabling patient data integration, target identification, patient stratification, and clinical trial simulation. Achieved 50% faster enrollment projections and 30% improved dose optimization for patients.
Partnerships: Collaborations with Roche, Sanofi, Bayer, and Merck KgAa. Achieved fourth milestone in Sanofi partnership and developed phenomaps with Roche for neuroscience and GI-Onc applications. Potential for over $100 million in partnership milestones by 2026.
Operational efficiencies: Reduced cash burn by 35% since 2024, with a projected burn below $390 million in 2026. Strong cash balance of $533 million and expected cash runway through Q4 2027.
Strategic shifts: Focus on differentiated, high-quality programs leveraging Recursion OS 2.0 and ClinTech platform. Emphasis on integrating AI and multimodal maps for drug discovery and clinical development.
Regulatory Changes Impacting R&D Tax Credits: The company highlighted that changes in U.K. legislation will reduce the size of R&D tax credits they receive in the future, which could impact cash inflows.
Challenges in Targeting CDK7: CDK7 has been an important target but has faced challenges with permeability, efflux, and absorption, which the company is attempting to address through AI-driven molecule design.
RBM39 Development Risks: RBM39 is a first-in-class target with potential challenges in identifying the right patient populations and ensuring effective degradation mechanisms for solid tumors.
Dependence on Partnerships: The company relies heavily on partnerships with Roche, Sanofi, Bayer, and Merck KgAa for milestones and funding, which could pose risks if partnerships do not progress as planned.
Cash Burn and Financial Sustainability: Despite reducing cash burn by 35% since 2024, the company still projects significant cash burn through 2026, with a runway only through Q4 2027, excluding additional partner inflows or financing.
Clinical Trial Execution Risks: While the company is leveraging AI to improve trial design and recruitment, there are inherent risks in achieving faster enrollment and ensuring trial success.
Platform Integration Challenges: The integration of Exscientia's platform into Recursion OS 2.0 is complex and may face challenges in achieving seamless functionality and delivering expected efficiencies.
Revenue and Partnership Inflows: The company projects over $100 million in partnership inflows by the end of 2026. This includes milestone payments from partnerships with companies like Sanofi, Roche, Bayer, and Merck KgAa.
Cash Burn and Financial Management: The company expects to manage its cash burn below $390 million in 2026, with a cash runway projected through Q4 2027. This projection excludes additional partner inflows or financing.
Clinical Trial Advancements: Recursion anticipates multiple clinical trial readouts over the next 18 months, including:
Platform Development and Efficiency: The Recursion OS 2.0 platform is expected to enhance drug discovery and clinical trial efficiency. The company aims to bring medicines to the clinic faster and at lower costs, leveraging AI-powered tools and iterative learning cycles.
Partnership Milestones: The company achieved its fourth milestone in the Sanofi partnership and expects to achieve over $100 million in partnership milestones by the end of 2026.
Pipeline Expansion: The company plans to expand its internal pipeline with high-quality, differentiated programs, including oncology and rare disease targets. New programs will integrate advanced AI and machine learning tools from the Recursion OS 2.0 platform.
The selected topic was not discussed during the call.
The earnings call highlights strong financial management, with a robust cash position and significant partnership inflows, particularly from Roche and Genentech. The company has reduced expenses by 35% and has a clear runway through 2027 without additional financing. The Q&A session revealed positive analyst sentiment, with management providing detailed and clear responses. The focus on AI-driven platform development and the strategic partnerships with major players like Sanofi and Roche further bolster confidence. Given these factors, the stock is likely to see a positive movement over the next two weeks.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
